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MicroparticleExtracellular ATP induces cation ﬂuxes in and impairs the growth of murine erythroleukemia (MEL) cells in a
manner characteristic of the purinergic P2X7 receptor, however the presence of P2X7 in these cells is
unknown. This study investigated whether MEL cells express functional P2X7. RT-PCR, immunoblotting and
immunoﬂuorescence staining demonstrated the presence of P2X7 in MEL cells. Cytoﬂuorometric
measurements demonstrated that ATP induced ethidium+ uptake into MEL cells in a concentration-
dependent fashion and with an EC50 of ∼154 μM. The most potent P2X7 agonist 2′- and 3′-0(4-
benzoylbenzoyl) ATP, but not ADP or UTP, induced ethidium+ uptake. ATP-induced ethidium+ and YO-
PRO-12+ uptake were impaired by the P2X7 antagonist, A-438079. A colourmetric assay demonstrated that
ATP impaired MEL cell growth. A cytoﬂuorometric assay showed that ATP induced MEL cell death and that
this process was impaired by A-438079. Finally, cytoﬂuorometric measurements of Annexin-V binding and
bio-maleimide staining demonstrated that ATP could induce rapid phosphatidylserine exposure and
microparticle release in MEL cells respectively, both of which were impaired by A-438079. These results
demonstrate that MEL cells express functional P2X7, and indicate that activation of this receptor may be
important in the death and release of microparticles from red blood cells in vivo.l) ATP; PS, phosphatidylserine;
T, thiazolyl blue tetrazolium
inomycin D; Ab, antibody; MFI,
+61 2 4221 4135.
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It is now ﬁrmly established that extracellular nucleotides and
nucleosides operate through a complex network of purinergic
signalling cascades involving various integral membrane receptors
and ectoenzymes [1–4]. One suchmember of this network is the P2X7
receptor, a trimeric ligand-gated cation channel belonging to the
family of P2X receptors [2,5]. Activation of P2X7 by ATP causes the
movement of Ca2+, Na+ and K+ across the plasma membrane, as well
as the uptake of organic cations including ﬂuorescent dyes such as
ethidium+ and YO-PRO-12+ [5,6]. P2X7 is also activated by 2′- and 3′-
0(4-benzoylbenzoyl) ATP (BzATP) but not other nucleotides such as
ADP and UTP, while its relative function is increased in the absence of
extracellular Ca2+, Na+ and Mg2+ ions [5,6]. P2X7 activation induces
an array of downstream events, in a cell speciﬁcmanner, including therapid exposure of phosphatidylserine (PS) and subsequent micropar-
ticle (MP) release in the form of either microvesicles or exosomes [7],
as well as cell death [8].
P2X7 is predominately expressed on mononuclear leukocytes [9]
and epithelial cells [10], and osteoblasts and osteoclasts [11], where it
plays a role in inﬂammatory and immune responses [12,13] and bone
homeostasis [14] respectively. P2X7 is also present in mature red
blood cells (erythrocytes) but its physiological role is not well
deﬁned. P2X7 has been observed in erythrocytes from several species
where it mediates ATP-induced cation ﬂuxes, epoxyeicosatrienoic
acid release, PS exposure and cell death [15–20]. However, with the
exception of P2X7 mRNA in human reticulocytes [21,22], the
expression of P2X7 in immature red blood cells is limited. Over
25 years ago, Chatawala and Cantley observed that extracellular ATP
could induce Ca2+, Na+ and K+ ﬂuxes in and impair the growth of
murine erythroleukemia (MEL) cells [23], a commonly usedmodel of
red blood cell biology [24]. Although not considered at the time, the
ATP-induced cation ﬂuxes in MEL cells were characteristic of P2X7,
being maximal at 1 mM ATP and with an EC50 value of ∼700 μM,
andwere increased in the absence of extracellular Ca2+ andNa+ [23].
Collectively this data suggested that MEL cells express P2X7,
however the identity of the receptor in these cells has never been
conﬁrmed.
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we report that MEL cells express P2X7, and that activation of this
receptor in these cells by ATP induces organic cation uptake and cell
death, as well as rapid PS exposure and MP release. This cell line will
provide a useful model for future studies of P2X7 in red cell biology,
and suggests that P2X7 may be important in the death and release of
microparticles from red blood cells in vivo.
2. Materials and methods
2.1. Materials
RPMI-1640 medium, fetal calf serum (heat-inactivated before
use), horse serum and L-glutamine were from Invitrogen (Grand
Island, NY). ATP, BzATP, ADP, UTP, ethidium bromide and thiazolyl
blue tetrazolium bromide (MTT) were from Sigma (St. Louis, MO). A-
438079 was from Tocris Bioscience (Ellisville, MO). Rat anti-murine
P2X7 monoclonal antibody (mAb) (clone HANO43) and 7-aminoacti-
nomycin D (7AAD) were from Alexis Biochemicals (Lausen,
Switzerland). Rat IgG2a isotype control mAb and FITC-conjugated
murine anti-rat IgG polyclonal antibody (Ab) were from eBioscience
(San Diego, CA). Rabbit anti-rat P2X7 (C-termini epitope) polyclonal
Ab and blocking peptide (used according to the manufacturer's
instructions) were fromAlomone Labs (Jerusalem, Israel). Peroxidase-
conjugated goat anti-rabbit IgG Ab was from Rockland (Gilbertsville,
PA). Protease inhibitor cocktail tablets (complete, Mini, EDTA-free),
phenyl-methyl-sulfonyl-ﬂuoride and Annexin-V-FLUOS were from
Roche Diagnostics (Pensberg, Germany). SuperSignal® West Pico
Chemiluminescent Substrate was from Pierce (Rockford, IL). YO-PRO-
12+ and bio-maleimide, alternatively known as BODIPY FL N-(2-
aminoethyl)maleimide, were from Molecular Probes (Invitrogen,
Eugene, OR). Fluoresbrite YG 0.5 μm microspheres were from
Polysciences Inc. (Warrington, PA). Flow-Count ﬂuorospheres were
from Beckman Coulter (Fullerton, CA). Other reagent grade chemicals
were from Sigma or Amresco (Solon, OH).
2.2. Cells
RAW264.7 cells were obtained from the American Type Culture
Collection (Manassas, VA). MEL cells were kindly provided by Dr. Sally
A. Eaton (University of Sydney, Sydney, Australia). Both cell lines were
maintained in complete culture medium (RPMI-1640 medium
containing 10% fetal calf serum and 5 mM L-glutamine) at 37 °C and
95% air/5% CO2. RAW264.7 cells were harvested by cell scraping.
2.3. P2X7 expression by RT-PCR
Total RNA was isolated from cells using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufacturer's instruc-
tions. PCR ampliﬁcation was performed using Superscript™ III One-
Step RT-PCR System Platinum Taq DNA polymerase (Invitrogen), and
forward primer 5′-ATATCCACTTCCCCGGCCAC-3′ and reverse primer
5′-TCGGCAGTGATGGGACCAG-3′ (GeneWorks, Hindmarsh, Australia)
[25] for 42 cycles (94 °C, 1 min; 54 °C, 1 min; 72 °C, 1 min) as des-
cribed [26]. PCR products were separated on a 2% agarose gel and
visualised using ethidium bromide staining.
2.4. P2X7 expression by immunoblotting
Cells were washed three times in ice-cold PBS and then lysed
(1×107 cells/ml) in ice-cold 50 mM BisTris (pH 7.0) containing
750 mM 6-aminohexanoic acid, 1% n-dodecyl β-D-maltoside, 1 mM
phenyl-methyl-sulfonyl-ﬂuoride and a protease inhibitor cocktail
over 60 min, sheared 10 times through a 21 G needle and centrifuged
(16,000×g for 10 min at 4 °C). Cell supernatants (equivalent to
1×105 cells/well) were then separated under reducing conditions(5% 2-mercaptoethanol) using 4–20% gradient iGels (NuSep, Austell,
GA) and transferred to nitrocellulosemembranes (Bio-Rad, Hercules,
CA). Nitrocellulose membranes were blocked overnight at 4 °C
with Tris-buffered saline (250 mM NaCl and 50 mM Tris, pH 7.5)
containing 0.2% Tween-20 and 5% skim milk powder, and then
incubated for 2 h at room temperature with anti-P2X7 Ab diluted in
Tris-buffered saline containing 0.2% Tween-20 and 5% skim milk
powder. Membraneswerewashed three times over 30 minwith Tris-
buffered saline containing 0.2% Tween-20 and then incubated for 1 h
at room temperature with peroxidase-conjugated anti-rabbit IgG
antibody diluted in Tris-buffered saline containing 0.2% Tween-20
and 5% skim milk powder. Membranes were washed as above,
incubated with chemiluminescent substrate and visualised using
Amersham Hyperﬁlm ECL (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK).
2.5. P2X7 expression by immunoﬂuorescence staining
Cells in PBS containing 10% horse serum and 0.01% NaN3 (1×106
cells/100 μl) were incubated with isotype control or anti-P2X7 mAb
for 30 min room temperature, washed twice with PBS containing
0.01% NaN3, incubated with FITC-conjugated murine anti-rat IgG
polyclonal Ab and 7AAD (to exclude dead cells) for 30 min at room
temperature, and washed as above. Data was collected using a LSR II
ﬂow cytometer (BD Biosciences, San Diego, CA) and the mean ﬂuores-
cence intensity (MFI) determined using FlowJo software (Tree Star,
Ashland, OR).
2.6. Fluorescent cation dye uptake assay
P2X7-induced pore formation was assessed using a ﬁxed-time
assay as described [27]. Brieﬂy, cells resuspended in NaCl medium
(145 mM NaCl, 5 mM KCl, 5 mM glucose, 0.1% bovine serum albumin,
and 10 mM HEPES, pH 7.5) (1×106 cells/ml) were incubated with
25 μM ethidium+ (or 1 μM YO-PRO-12+ were indicated) in the
absence or presence of nucleotide for 5 to 15 min as indicated at
37 °C. Incubationswere stopped by addition of an equal volume of ice-
cold NaCl medium containing 20 mM MgCl2 (MgCl2 medium) and
centrifugation (300×g for 5 min). Cells were washed once with NaCl
medium. In some experiments, cells were pre-incubated in the
absence or presence of 10 μMA-438079 for 15 min at 37 °C before the
addition of ethidium+ or YO-PRO-12+. Data was collected by ﬂow
cytometry and the MFI of ethidium+ uptake determined using FlowJo
software.
2.7. Measurement of cell growth by the MTT assay
MEL cells in complete culture media in 96-well plates (5×104
cells/100 μl/well) were incubated in the absence or presence of ATP
(as indicated) for 24 h at 37 °C and 95% air/5% CO2. During the ﬁnal
4 h of ATP incubation, 0.5 mg/ml MTT was added (10 μl/well). Cells
were then incubated with 10 mM HCl containing 10% SDS (solubili-
zation solution) (100 μl/well) overnight at 37 °C. Absorbances were
read at a wavelength of 550 nm and a reference wavelength of
690 nm using a SpectaMax Plus384 microplate reader (Molecular
Devices, Sunnyvale, CA).
2.8. Measurement of cell death by a cytoﬂuorometric assay
MEL cells in complete culture media in 24-well plates (5×105
cells/ml/well) were incubated in the absence or presence of 2 mM
ATP for 24 h at 37 °C and 95% air/5% CO2. In some experiments, cells
were pre-incubated in the absence or presence of 10 μMA-438079 for
15 min at 37 °C before the addition of ATP. Following incubation with
ATP, cells were harvested and washed once with NaCl medium
containing 5 mM CaCl2. Cells in 100 μl NaCl medium containing 5 mM
Fig. 1. P2X7 is present on MEL cells. (A) RNA was isolated from RAW264.7 and MEL
cells, and analysed by RT-PCR using primers to P2X7. RNA substituted with H2O was
used as a negative control. PCR products were visualised using ethidium bromide.
(B) Whole cell lysates of RAW264.7 and MEL cells were separated by electrophoresis,
transferred to nitrocellulose membrane and probed with anti-P2X7 Ab, pre-incubated
in the absence (Ab) or presence of blocking peptide (Peptide/Ab). (C) RAW264.7 and
MEL cells were labelled with anti-P2X7 (solid line) or isotype control (shaded) mAb, and
with FITC-conjugated anti-rat IgG Ab and 7AAD (to exclude dead cells), and analysed by
ﬂow cytometry. Results are representative of 2–3 experiments.
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15 min at room temperature, before addition of 400 μl NaCl medium
containing 5 mMCaCl2. Data was collected by ﬂow cytometry, and the
cells gated to exclude dust particles and small cellular debris (events
of low forward and side scatter), and the percentage of Annexin-V+/
7AAD−, Annexin-V+/7AAD+ and Annexin-V−/7AAD+ cells within
the gate determined using FlowJo software.
2.9. PS exposure assay
Cells were resuspended in PS exposure assay medium (147 mM
NaCl, 2 mM KCl, 12 mM glucose, 2.5 mM CaCl2, 1 mM MgCl2, and
10 mM HEPES, pH 7.5) (1×106 cells/500 μl) and pre-incubated in the
absence or presence of 10 μMA-438079 for 15 min at 37 °C. Cells were
then incubated with Annexin-V-FLUOS in the absence or presence of
2 mM ATP for a further 5 min at 37 °C. Incubations were stopped by
addition of an equal volume of ice-cold MgCl2 medium and
centrifugation (300×g for 5 min). Cells were washed once with
NaCl medium and incubated with 7AAD (to exclude dead cells) for
5 min before ﬂow cytometric analysis to determine the MFI of
Annexin-V-FLUOS binding using FlowJo software.
2.10. MP release assay
ATP-induced MP release was conducted as previously described
[28]. Adherent RAW264.7 cells or suspended MEL cells in MP release
assay medium (147 mMNaCl, 2 mM KCl, 12 mM glucose, 2 mM CaCl2,
1 mM MgCl2, and 10 mM HEPES, pH 7.5; 0.2 μM ﬁltered) in 24-well
plates (0.5×106 cells/500 μl/well) were incubated in the absence or
presence of 2 mM ATP for 10 min at 37 °C and 95% air/5% CO2.
Incubations were stopped by centrifugation (300×g for 5 min) and
450 μl of each supernatant collected. In some experiments, cells were
pre-incubated in the absence or presence of 10 μM A-438079 for
15 min at 37 °C before the addition of ATP.
The amount of MPs in each supernatant was then quantiﬁed using
bio-maleimide as previously described [29,30]. Brieﬂy, supernatants
(450 μl) were incubated with 25 μl of 50 μMbio-maleimide for 15 min
at room temperature. Then to each sample, 25 μl of Flow-Count
ﬂuorospheres was added, the samples vortexed and analysed by ﬂow
cytometry collecting 2000 events within the Flow-Count ﬂuoro-
spheres gate. Amounts of bio-maleimide+ MPs per ml were then
enumerated based on the number of Flow-Count ﬂuorospheres
according to the manufacturer's instructions. Fluoresbrite YG 0.5 μm
microspheres, suspended in MP release assay medium, were also
analysed by ﬂow cytometry and used to approximate the size of MPs.
All data was analysed using FlowJo software.
2.11. Presentation of data, statistics and nomenclature
Results are represented as means±SD. Data was compared using
either the unpaired Student's t-test for single comparisons or one-way
analysis of variance (using Tukey's post test) for multiple comparisons
using Prism 5 for Mac OS X Version 5.0a (GraphPad Software,
San Diego, CA) with Pb0.05 considered signiﬁcant. The nomenclature
for P2X7, rather than P2X7, has been adopted according to recent
guidelines [5,31,32].
3. Results
3.1. P2X7 is expressed in MEL cells
In order to determine if MEL cells express P2X7, mRNA was isolated
and ampliﬁed by RT-PCR. RAW264.7 cells, which are well known to
express P2X7 [27,28,33,34], were included as a positive control. P2X7
mRNAwasexpressed in both cell types (Fig. 1A).Next,whole cell lysates
were prepared and the presence of P2X7 protein examined byimmunoblotting. Immunoblotting with an anti-P2X7 polyclonal Ab
revealed the presence of a major band at 75 kDa, the predicted size of
P2X7, in both RAW264.7 and MEL cells (Fig. 1B). Pre-incubation of the
anti-P2X7 polyclonal Ab with blocking peptide abolished immunoreac-
tivity (Fig. 1B). Finally, cells were incubated with an anti-P2X7 mAb
[35] and examined by ﬂow cytometry. Immunolabelling demonstrated
cell-surface P2X7 expression on RAW264.7 and MEL cells with a MFI
of 25.6±12.1 and 5.2±3.0 respectively (Fig. 1C). Collectively, these
results indicate that MEL cells express P2X7.
3.2. P2X7 agonists induce ethidium+ uptake into MEL cells
Next, a ﬁxed-time ethidium+ uptake assay [27] was used to
determine if P2X7 on MEL cells is functional. Again RAW264.7 cells
Fig. 2. ATP induces ethidium+ uptake into MEL cells. RAW264.7 and MEL cells in NaCl
medium containing 25 μM ethidium+ were incubated in the absence (basal) or
presence of 1 mM ATP at 37 °C for up to 15 min. Incubations were stopped by addition
of MgCl2 medium and centrifugation, and the cells analysed by ﬂow cytometry. Results
are mean±SD (n=3); where SDs are not visible, SDs are≤1.1; ⁎⁎Pb0.01 compared to
corresponding basal.
Fig. 3. P2X7 agonists induce ethidium+ uptake intoMEL cells. MEL cells in NaClmedium
containing 25 μM ethidium+ were incubated at 37 °C for 15 min in the (A) absence or
presence of varying ATP concentrations (as indicated), or (B) in the absence (basal) or
1 mM agonist (except BzATP, 200 μM). Incubations were stopped by addition of MgCl2
medium and centrifugation, and the cells analysed by ﬂow cytometry. Ethidium+
uptake is expressed as (A) percent maximum response compared to 2 mM ATP or
(B) mean ﬂuorescence intensity. Results are mean±SD (n=3); ⁎⁎Pb0.01 compared to
basal.
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[28,34], ATP induced ethidium+ uptake into RAW264.7 cells in a time-
dependent manner (Fig. 2). ATP also induced ethidium+ uptake into
MEL cells in a time-dependent manner (Fig. 2), although the level of
uptake was lower than that of RAW264.7 cells. Ethidium+ uptake in
the absence of ATP was similar in both cell lines (Fig. 2).
MEL cells were then incubated with increasing concentrations of
ATP. ATP induced ethidium+ uptake in a concentration-dependent
manner, withmaximal uptake occurring at 1 to 2 mMATP andwith an
EC50 of 154±13 μM (Fig. 3A). MEL cells were also incubated in the
presence of the most potent P2X7 agonist BzATP, as well as ADP and
UTP, which do not activate P2X7 [36]. BzATP, but not ADP or UTP,
induced ethidium+ uptake into MEL cells (Fig. 3B).
3.3. A P2X7 antagonist impairs ATP-induced ethidium+ uptake into
MEL cells
To conﬁrm that the ATP-induced ethidium+ uptake into MEL cells
was mediated by P2X7, cells were pre-incubated in the absence or
presence of the P2X7 antagonist A-438079 [37]. Pre-incubation with
A-438079 signiﬁcantly inhibited ATP-induced ethidium+ uptake into
MEL cells by 80±2% (Fig. 4A). To determine if P2X7 activation could
induce the uptake of a second cation, cells were pre-incubated in the
absence or presence of A-438079, and ATP-induced YO-PRO-12+
uptake examined. As for ethidium+, ATP induced YO-PRO-12+ uptake
into MEL cells, and pre-incubation with A-438079 signiﬁcantly
impaired this uptake by 79±9% (Fig. 4B).
3.4. P2X7 induces cell death in MEL cells
A previous study has shown that extracellular ATP impairs the
growth of MEL cells [23], however the mechanism was never deter-
mined. Therefore, to conﬁrm if extracellular ATP can impair the
growth of MEL cells, cells were incubated with increasing concentra-
tions of ATP and the relative cell number (expressed as absorbance)
determined using the MTT assay. ATP reduced cell numbers in a
concentration-dependent manner, with a maximal reduction occur-
ring at 2 mM ATP (Fig. 5).
The MTT assay measures metabolic activity rather than cell
numbers directly, thus the decrease in absorbances following ATPincubation may be a result of decreased metabolic activity rather than
decreased cell numbers (as a result of either cell death or reduced
proliferation). However, given the well-known cytolytic role of P2X7
in various cell types [8], we reasoned that the reduced absorbances
following ATP incubation were due to increased cell death. Therefore,
MEL cells were incubated with 2 mM ATP for 24 h, and the amount of
cell death was determined by ﬂow cytometry using Annexin-V
binding (PS exposure) and 7AAD uptake (loss of plasma membrane
integrity) (Fig. 6A). Incubation with 2 mM ATP induced an approx-
imately 3.1-fold increase in Annexin-V+ and 7AAD+ cells, which
represents either necrotic or late apoptotic cells or a combination of
both [38], compared to cells incubated in the absence of ATP (basal)
(Fig. 6B). Incubation with 2 mMATP resulted in an approximately 3.3-
fold and 1.6-fold increase in Annexin-V+/7AAD− (early apoptotic)
cells and Annexin-V−/7AAD+ (necrotic) cells compared to basal cells
(Fig. 6B).
To determine if ATP induced MEL cell death via activation of P2X7,
cells were pre-incubated in the absence or presence of A-438079,
before overnight incubation in the absence or presence of 2 mM ATP.
As above, incubation with 2 mM ATP induced a signiﬁcant increase in
Annexin-V+/7AAD– (Fig. 7A) and Annexin-V+/7AAD+ cells (Fig. 7B)
compared to basal cells. In contrast, 2 mM ATP induced a small in-
crease in the percentage Annexin-V−/7AAD+cells compared to basal
cells, but this failed to reach statistical signiﬁcance (results not shown).
Fig. 4. The P2X7 antagonist, A-438079, impairs ATP-induced ethidium+ and YO-PRO-12+
uptake into MEL cells. MEL cells in NaCl medium were pre-incubated in the absence or
presence of 10 μM A-438079 at 37 °C for 15 min, and then with (A) 25 μM ethidium+ or
(B) 1 μMYO-PRO-12+ in the absence (basal) or presence of 1 mMATP at 37 °C for 15 min.
Incubations were stopped by addition of MgCl2 medium and centrifugation, and the cells
analysed by ﬂow cytometry. Results are mean±SD (n=3); ⁎Pb0.05 and ⁎⁎Pb0.01
compared to corresponding basal; ††Pb0.01 compared to ATP alone.
Fig. 6. ATP induces cell death in MEL cells. MEL cells in complete culture media were
incubated in the absence (basal) or presence of 2 mM ATP at 37 °C for 24 h. Cells were
harvested, and incubated with Annexin-V-FLUOS and 7AAD, and analysed by ﬂow
cytometry. (A) Representative dot plots shown (B)with results expressed asmean±SD
(n=3); ⁎⁎Pb0.01 compared to corresponding basal.
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duced increase of Annexin-V+/7AAD− and Annexin-V+/7AAD+ cells
by 88±6% and 78±15% respectively (Fig. 7).Fig. 5. ATP impairs the growth of MEL cells. MEL cells in complete culture media were
incubated in the absence (basal) or presence of ATP (as indicated) at 37 °C for 24 h. MTT
was added during the ﬁnal 4 h, before overnight incubation with solubilization solution
at 37 °C. Absorbances were then read at 550 and 690 nm. Results are mean absorbances
(A550 nm−A690 nm)±SD (n=3); ⁎⁎Pb0.01 compared to basal.3.5. P2X7 induces rapid PS exposure and MP release in MEL cells
P2X7 activation can induce MP release from various cell types,
which is preceded by the rapid and reversible exposure of PS on the
cell-surface which can be measured by Annexin-V binding [7].
Therefore, the ability of P2X7 activation to induce MP release from
MEL cells was ﬁrstly studied indirectly by assessing P2X7-induced
rapid PS exposure. Cells were pre-incubated in the absence or presence
of A-438079, and then for 5 min in the presence of Annexin-V in the
absence or presence of ATP. In the absence of A-438079, ATP caused
signiﬁcantly higher amounts of Annexin-V binding on MEL cells,
compared to cells incubated in the absence of ATP (Fig. 8). Pre-
incubationwithA-438079 reduced the amountof Annexin-Vbindingby
63±3% (Fig. 8).
The above results indicate that P2X7 activation can induce rapid PS
exposure in MEL cells, and that P2X7 activation may also lead to MP
from these cells. Therefore, using incubation conditions previously
used for RAW264.7 cells [28], MEL cells, as well as positive control
RAW264.7 cells, were incubated in the absence or presence of ATP for
10 min as described [28]. The amount of MP released into the
supernatants was then quantiﬁed using the MP stain, bio-maleimide
[29,30] and ﬂow cytometry (Fig. 9). Incubation of RAW264.7 cells
with ATP resulted in an approximately 1.7-fold increase in the release
of MPs into the extracellular medium compared to RAW264.7 cells
Fig. 7. The P2X7 antagonist, A-438079, impairs ATP-induced cell death in MEL cells.
MEL cells in complete culture media were pre-incubated in the absence or presence of
10 μM A-438079 at 37 °C for 15 min, and then incubated in the absence (basal) or
presence of 2 mM ATP at 37 °C for 24 h. Cells were harvested, and incubated with
Annexin-V-FLUOS and 7AAD, and analysed by ﬂow cytometry. Results are mean±SD
(n=3); ⁎⁎Pb0.01 compared to corresponding basal; ††Pb0.01 compared to ATP alone.
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MPs/ml respectively, n=9, P=0.007; Fig. 9A). Similarly, incubation
of MEL cells with ATP resulted in an approximately 1.9-fold increase
in the release of MPs into the extracellular medium compared to
MEL cells incubated in the absence of ATP (54321±23358 versus
28027±14377 MPs/ml respectively, n=9, P=0.011; Fig. 9B). ToFig. 8. P2X7 activation mediates ATP-induced rapid PS exposure in MEL cells. MEL cells
in PS exposure assay medium were pre-incubated in the absence or presence of 10 μM
A-438079 at 37 °C for 15 min, and then with Annexin-V-FLUOS in the absence (basal)
or 2 mMATP at 37 °C for 5 min. Incubations were stopped by addition of MgCl2 medium
and centrifugation. Cells were incubated for 5 min with 7AAD (to exclude dead cells),
and then analysed by ﬂow cytometry. Results are mean±SD (n=3); ⁎⁎Pb0.01
compared to corresponding basal; ††Pb0.01 compared to ATP alone.
Fig. 9. ATP induces MP release from MEL cells. (A) Adherent RAW264.7 cells or
(B) suspended MEL cells in MP release assay medium were incubated in the absence
(basal; left hand plots) or presence of 2 mM ATP (right hand plots) at 37 °C for 10 min.
Incubations were stopped by centrifugation and supernatants collected. Supernatants
were incubated with 2.5 μM bio-maleimide for 15 min. Then to each sample, Flow-
Count ﬂuorospheres were added, the samples vortexed and analysed by ﬂow
cytometry. MPs were gated by forward and side scatter, and then the amount of bio-
maleimide+ MPs per ml enumerated. Representative dot plots of 9 experiments are
shown.determine if the ATP-induced MP release was mediated by P2X7, cells
were pre-incubated in the absence or presence of A-438079. Pre-
incubation with A-438079 signiﬁcantly inhibited MP release from
RAW264.7 andMEL cells by 83±2% and 71±11% respectively (Fig. 10).
4. Discussion
Over 25 years ago, Chatawala and Cantley reported that extracel-
lular ATP could induce Ca2+, Na+ and K+ ﬂuxes in and reduce the
growth of MEL cells [23]. These ATP-induced effects were character-
istic of P2X7, however this receptor was not considered at the time.
Therefore, we hypothesised that this murine erythroleukemia cell line
expresses functional P2X7 receptors. Our study supports this
hypothesis. First, RT-PCR and immunoblotting demonstrated that
P2X7 mRNA and protein respectively were present in MEL cells.
Fig. 10. The P2X7 antagonist, A-438079, impairs ATP-induced MP release from MEL
cells. (A) Adherent RAW264.7 cells or (B) suspended MEL cells in MP release assay
medium were pre-incubated in the absence or presence of 10 μM A-438079 at 37 °C for
15 min, and then in the absence (basal) or presence of 2 mM ATP at 37 °C for 10 min.
Incubations were stopped by centrifugation and supernatants collected. Supernatants
were incubated with 2.5 μM bio-maleimide for 15 min. Then to each sample, Flow-
Count ﬂuorospheres were added, the samples vortexed and analysed by ﬂow cyto-
metry. Results are mean±SD (n=9); ⁎⁎Pb0.01 compared to corresponding control;
†Pb0.05 compared to ATP alone.
1803P. Constantinescu et al. / Biochimica et Biophysica Acta 1798 (2010) 1797–1804Second, immunoﬂuorescence staining revealed the presence of P2X7
on MEL cells. Third, ATP induced ethidium+ uptake into MEL cells
with an EC50 value typical of ATP-induced cation ﬂuxes mediated by
recombinant P2X7 [36]. Fourth, BzATP, but not ADP or UTP induced
ethidium+ uptake into MEL cells, again typical of recombinant P2X7
[36]. Fifth, ATP-induced ethidium+ and YO-PRO-1+ uptake into MEL
cells was impaired by the speciﬁc P2X7 antagonist, A-438079 [37].
Finally, ATP could induce cell death, rapid PS exposure and MP release
from MEL cells, and each of these events, which are commonly
associated with P2X7 activation [7,8], could be impaired by A-438079.
P2X7 activation could induce cell death in MEL cells. Chatawala
and Cantley reported that extracellular ATP could inhibit the growth
of MEL cells [23], however whether this was due to a block in cell
division or due to increased cell death was never established. Our
study conﬁrmed that extracellular ATP could impair MEL cell growth,
and further demonstrated that this effect was a result of P2X7-
induced cell death. In the cytoﬂuorometric assay, the Annexin-V−/
7AAD+ cells most likely represented early apoptotic cells, however
whether the Annexin-V+/7AAD+ cells represented late apoptotic or
necrotic cells, or both cannot be exclusively determined using only
these two markers of cell death [38]. We have previously shown that
P2X7 activation can induce PS exposure and haemolysis in canine
erythrocytes [18], while others have shown that the bacterial
virulence factor, α-hemolysin, can induce haemolysis of murine,
human and equine erythrocytes in a P2X7-dependent fashion [16].
P2X7 activation is known to induce cell death in a variety of cell types
[8], however the physiological role of P2X7-induced cell deathremains obscure. Studies of P2X7 deﬁcient mice suggest that the
receptor is not involved in regulating cell numbers under normal,
physiological conditions [39,40], except in bone homeostasis [11].
Both human and murine studies indicate that P2X7-induced macro-
phage death may play a role in controlling intracellular bacterial
infections [12], while impaired P2X7-induced cell death may promote
epithelial malignancies [41]. Thus, we hypothesise that P2X7
activation may play a role in removing either wanted or unwanted
cells, including red blood cells, during various disease states including
infection and malignancy, but not during normal homeostasis, with
the exception of bone homeostasis.
P2X7 activation could also induce MP release from MEL cells. Using
incubation conditions previously used to study P2X7-induced MP
release from RAW264.7 macrophages [28], coupled with a cytoﬂuoro-
metric assay utilising the MP stain, bio-maleimide [29,30], we
demonstrated that P2X7 activation could induce rapid PS exposure
andMP release fromMEL cells. P2X7 activation can induceMP release in
the form ofmicrovesicles or exosomes from various cell types including
macrophages,microglia, dendritic cells and endothelial cells [28,42–45].
MPs released from these cell types can promote either coagulation or
inﬂammation through the expression of tissue factor and PS, or
interleukin-1β and major histocompatibility class II complexes respec-
tively. Althoughwe have not speciﬁcally characterised theMPs released
following P2X7 activation in our study, using microspheres we
estimated the MPs to be approximately 0.5 μM in diameter (results not
shown), which is within the range (0.1 to 1 μM in diameter) of
microvesicles [46]. It is possible, that P2X7 activation may have also
induced the release of smaller MPs, butwas beyond the detection limits
of the cytoﬂuorometric technique used in our study.Moreover, whether
the MPs detected in our study represent true microvesicles or simply
membrane fragments is unknown. Nevertheless, our study provides the
ﬁrst evidence thatP2X7activation can induceMP release fromredblood
cells. Microvesiculation or MP release is a well-described phenomenon
in both reticulocytes and erythrocytes, where it is postulated to play an
important role during the terminal differentiation of reticulocytes into
erythrocytes to remove no longer required cellular molecules or
organelles [47,48], and in extending erythrocyte life-span through the
removal of non-functional proteins and potential auto-antigens which
may cause the pre-mature removal of otherwise functional erythrocytes
[49,50]. Themechanisms however that lead to red blood cell MP release
in vivo and during the cold-storage of red blood cells are unknown. Thus,
our study suggests a possible role for P2X7 in these processes. It will be
of interest to characterise the nature of theMPs released fromMEL cells
following P2X7 activation, and whether P2X7 can induce MP release
fromprimary reticulocytes and erythrocytes in future in vitro and in vivo
studies.
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